← Back to search
HEALTH DECISIONS, INC.
MORRISVILLE, NC, 27560
Unclaimed
Small Business
Prime contracting experience
16 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | NICHD:R&D:CCTN STATISTICAL AND CLINICAL COORDINATING CENTER (SCCC) CORE FUNCTION ACTIVITIES:SEVERABLE | 75N94019D00004USAspending | $495,123 | Sep 18, 2026 | Sep 20, 2026 – Sep 19, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | NICHD: R&D: SUPPORTING THE PHASE IIB CLINICAL TRIAL OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE (LB) FOR FEMALE CONTRACEPTION: NON-SEVERABLE | 75N94019D00004USAspending | $1,286,724 | Sep 17, 2026 | Aug 1, 2025 – Mar 31, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | TASK ORDER 2: STATUS DETERMINATION AND PRIORITIZATION OF PIPELINE PRODUCTS UNDERGOING CLINICAL TRIALS FOR MALE AND FEMALE CONTRACEPTION | 75N94019D00004USAspending | $2,493,065 | Sep 10, 2026 | Sep 24, 2019 – Dec 31, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | FINALIZATION, PROCUREMENT OF REGULATORY APPROVAL, AND COMPLETE START-UP ACTIVITIES FOR THE OVAPRENE VAGINAL DEVICE CLINICAL TRIAL | 75N94019D00004USAspending | $2,187,390 | Jul 29, 2026 | Sep 1, 2023 – Jul 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | NICHD: R&D: COORDINATION, MONITORING, FOLLOW-UP, EVALUATION, AND COMPLETION OF A CLINICAL TRIAL OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION: NON-SEVERABLE | 75N94019D00004USAspending | $1,230,826 | May 13, 2026 | May 1, 2025 – Oct 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | STATISTICAL AND CLINICAL COORDINATING SERVICES FOR GROUPS C AND D OF CCN021 ENTITLED, "A STUDY TO EVALUATE THE PK AND PD OF IM OR SQ INJECTIONS OF LEVONORGESTREL BUTANOATE (LB) FOR FEMALE CONTRACEPTION" | 75N94019D00004USAspending | $2,330,144 | Apr 22, 2026 | May 25, 2023 – Oct 21, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS | HHSN275201200002IUSAspending | $3,170,829 | Sep 26, 2025 | Sep 24, 2013 – Dec 31, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | TO AWARD TASK ORDER 75N94019F0025, INTERNAL NO. TASK ORDER 1 TITLE CORE FUNCTION ACTIVITIES FOR THE "NICHD CCTN STATISTICAL AND CLINICAL COORDINATING CENTER" SEPTEMBER 20, 2019 - SEPTEMBER 19, 2020. | 75N94019D00004USAspending | $3,594,685 | Sep 16, 2025 | Sep 20, 2019 – Sep 19, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | ACQUISITION OF THE NESTORONE ESTRADIOL (NES/E2) VAGINAL RING | 75N94019D00004USAspending | $1,199,999 | Jul 14, 2025 | Sep 25, 2024 – Sep 25, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | COORDINATION, MONITORING, FOLLOW-UP, AND EVALUATION OF A CLINICAL TRIAL OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION | 75N94019D00004USAspending | $6,449,482 | Apr 21, 2025 | Jan 1, 2023 – Apr 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIALS NETWORK TO6 - COORDINATION OF CLINICAL TRIALS OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION - | HHSN275201200002IUSAspending | $7,374,299 | Oct 24, 2024 | Apr 13, 2016 – Apr 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | HHSN275201200002I/HHSN27500009 - CONTRACEPTIVE CLINICAL TRIALS NETWORK, CLINICAL EVALUATION OF LARC METHODS TO DETERMINE COMPARATIVE EFFECTIVENESS, ACCEPTABILITY, AND SAFETY - HEALTH DECISIONS, INC - CAN 8030701 | HHSN275201200002IUSAspending | $9,779,723 | Oct 22, 2024 | Jul 20, 2018 – Mar 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | PROTOCOL FINALIZATION, START-UP, COORDINATION, MONITORING, AND ALL OTHER ASSOCIATED ACTIVITIES FOR CLINICAL TRIALS EVALUATING PROGESTOGENIC ANDROGENS AS CONTRACEPTIVE AGENTS | 75N94019D00004USAspending | $994,099 | Oct 11, 2024 | Sep 25, 2024 – Sep 24, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF STATISTICAL AND CLINICAL COORDINATING CENTER FOR CCTN | HHSN275201200002IUSAspending | $3,945,011 | Jun 20, 2024 | Jul 20, 2017 – Oct 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE FUNCTION ACTIVITIES | HHSN275201200002IUSAspending | $2,499,794 | Apr 22, 2024 | Sep 20, 2012 – Sep 19, 2019 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF COORDINATION OF CLINICAL TRIALS OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION | HHSN275201200002IUSAspending | $10,032,586 | Jun 30, 2023 | Jul 18, 2017 – Jul 17, 2024 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced